ALPHA VAC

New therapeutic approach for the treatment of hepatitis C virus infection based on the combination of a therapeutic vaccine and a nanoparticle-based formulation of IFN

ALPHA VAC est accrédité par Lyonbiopôle

Identity card

Global budget: 6 900 k€

Public funding: 2 270 k€

Public funders: Conseil général de Rhône, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Grenoble Alpes Métropole, Région Rhône-Alpes

Call for projects: FUI (FUI AAP3)

Year start: 2007

Completed project (2012-07)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Human Medicines

Application fields: Infectious diseases

Technological approaches / Keywords: Immunotherapy, Vector vaccine

Stage of development at the beginning of the project: Preclinical development

Abstract

Alphavac aimed to develop a new therapeutic approach for the treatment of hepatitis C virus infection based on the combination of TG4040 immunotherapy product (Transgene) and long-acting interferon IFN-XL (Flamel) also to validate a diagnosis DNA chip (INSERM). The objectives have been achieved and two Phase II clinical trials have been initiated. The results show that IFN-XL has increased antiviral efficacy and the safety compared to standard interferon. Final data have shown that TG4040 in combinaison induced a decline in HCV viral load and that early response rates of standard therapy were increased.


Objectives

The objective was to develop a novel therapeutic approach for the treatment of chronic HCV infections based on the combination of a vectored therapeutic vaccine and an antiviral agent displaying adjuvant properties. - Establish the proof-of-concept, at the pre-clinical and clinical level, - Establish the preclinical proof-of-concept using the combination of the MVA vaccine and a slow-release formulation of IFN-alpha, - Finalize clinical safety and efficacy studies of the IFN-XL, - Organize the launching of a clinical trial to validate the IFN-XL and MVA combination in HCV patients.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

New therapeutic approach for the treatment of hepatitis C virus infection based on the combination of a therapeutic vaccine and a nanoparticle-based formulation of IFN

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte